Harrison Sudholz

Harrison Sudholz

Auto-generated profile, based on publicly available information

Harrison Sudholz

Division of Immunology and Molecular Medicine, Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
SLShuwei Liang
Shuwei Liang
ETEric Tran
Eric Tran
XDXin Du
Xin Du
JDJiajun Dong
Jiajun Dong
HSHarrison Sudholz
Harrison Sudholz
TTTony Tiganis
Tony Tiganis
The inhibition of protein tyrosine phosphatases 1B (PTP1B) and N2 (PTPN2) has emerged as an exciting approach for bolstering T cell anti-tumor immunity. ABBV-CLS-484 is a PTP1B/PTPN2 inhibitor in clinical trials for solid tumors. Here we have explored the therapeutic potential of a related small-molecule-inhibitor, Compound-182. We demonstrate that Compound-182 is a highly potent and selective active site competitive inhibitor of PTP1B and PTPN2 that enhances T cell recruitment and activation and represses the growth of tumors in mice, without promoting overt immune-related toxicities. The enhanced anti-tumor immunity in immunogenic tumors can be ascribed to the inhibition of PTP1B/PTPN2 in T cells, whereas in cold tumors, Compound-182 elicited direct effects on both tumor cells and T cells. Importantly, treatment with Compound-182 rendered otherwise resistant tumors sensitive to α-PD-1 therapy. Our findings establish the potential for small molecule inhibitors of PTP1B and PTPN2 to enhance anti-tumor immunity and combat cancer.

5 January 2024 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
WGWilford Goh
Wilford Goh
HSHarrison Sudholz
Harrison Sudholz
MFMomeneh Foroutan
Momeneh Foroutan
SSSebastian Scheer
Sebastian Scheer
APAline Pfefferle
Aline Pfefferle
Nicholas D HuntingtonNicholas D Huntington
Nicholas D Huntington

2 August 2025 in Cell Reports
Verified
Journal Article
Open access
HSHarrison Sudholz
Harrison Sudholz
XMXiangpeng Meng
Xiangpeng Meng
HPHae-Young Park
Hae-Young Park
ZSZihan Shen
Zihan Shen
INIva Nikolic
Iva Nikolic
Nicholas D HuntingtonNicholas D Huntington
Nicholas D Huntington
Natural killer (NK) cell homeostasis and effector functions require context-dependent signaling via numerous receptors, including the interleukin-15 receptor (IL-15R). Post-translational modifications can regulate receptor signaling, impacting receptor turnover and trafficking. Core fucosylation is one such modification known to impact receptor expression and is uniquely mediated by fucosyltransferase 8 (FUT8). We identified FUT8 as an essential gene required for IL-15R responsiveness in a human NK cell genome-wide CRISPR screen. To further validate core fucosylation in IL-15R signaling and NK cell biology, mice lacking Fut8 in NK cells (Fut8fl/flNcr1cre/+) were generated. The loss of core fucose in murine NK cells resulted in severe NK cell lymphopenia, with a reduction in IL-15Rβ (IL-2RB/CD122) expression, impairing in vivo homeostatic proliferation. The loss of FUT8 also decreased NK cell cytotoxicity, tumor immunity, and early viral immunity. Taking these results together, we have identified FUT8 as a key modulator of NK cell biology by regulating their development, IL-15R expression, and signaling.

17 July 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
YJYeara Jo
Yeara Jo
AKAlexandros Karampatzakis
Alexandros Karampatzakis
SLSeung Won Lee
Seung Won Lee
APAlice Peng
Alice Peng
ZGZaina Ghouri
Zaina Ghouri
DRDavid H. Raulet
David H. Raulet
Summary: Natural Killer (NK) cell desensitization induced by persistent stimulation limits durable antitumor immunity, yet the molecular mechanisms governing this dysfunctional state remain poorly defined. To identify conserved regulators of NK cell desensitization, we performed comparative transcriptomic analyses across multiple murine models of persistent activation and dysfunction. This approach defined a shared transcriptional program of desensitization and identified Itpkb to be upregulated across multiple distinct contexts. Genetic and pharmacological inhibition of ITPKB enhanced degranulation, cytokine production, and cytotoxicity in both murine and human NK cells under multiple desensitization settings. Mechanistically, ITPKB regulated signaling downstream of persistent activation through the IP 3 /IP 4 axis, limiting calcium mobilization and NFAT-dependent transcriptional responses in desensitized NK cells. Furthermore, inhibition or deletion of ITPKB enhanced NK-cell mediated tumor control in vivo and improved the efficacy of adoptively transferred CAR-NK cells, underscoring the translational potential of targeting this pathway. Together, these findings identify ITPKB as a cell-intrinsic regulator of NK cell desensitization and support targeting the IP 3 /IP 4 signaling axis to enhance NK cell-mediated antitumor immunity.